Hetlioz Lq is owned by Vanda Pharms Inc.

Hetlioz Lq contains Tasimelteon.

Hetlioz Lq has a total of 22 drug patents out of which 1 drug patent has expired.

Expired drug patents of Hetlioz Lq are:

• US5856529

Hetlioz Lq was authorised for market use on 01 December, 2020.

Hetlioz Lq is available in suspension;oral dosage forms.

Hetlioz Lq can be used as treatment of nighttime sleep disturbances in smith-magenis syndrome by administering tasimelteon, treatment of nighttime sleep disturbances in smith-magenis syndrome by avoiding the administration of tasimelteon with beta-adrenergic receptor antagonists, treatment of nighttime sleep disturbances in smith-magenis syndrome by avoiding the administration of tasimelteon to smokers or to patients being treated with a cyp1a2 inhibitor, treatment of nighttime sleep disturbances in smith-magenis syndrome by avoiding the use of tasimelteon with rifampin, treatment of nighttime sleep disturbances in smith-magenis syndrome by avoiding the avoiding the use of tasimelteon in combination with a strong cyp1a2 inhibitor, treatment of nighttime sleep disturbances in smith-magenis syndrome by avoiding the administration of tasimelteon with food, treatment of nighttime sleep disturbances in smith-magenis syndrome non-24 hour sleep-wake disorder by avoiding the use of tasimelteon in combination with cyp1a2 strong inhibitors, treatment of nighttime sleep disturbances in smith-magenis syndrome by administering tasimelteon to patients with a smoking history.

The generics of Hetlioz Lq are possible to be released after 21 February, 2041.